Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

WLY - John Wiley & Sons, Inc. Latest News | Finranks

Home

WLY

J

John Wiley & Sons, Inc. (WLY)

NYQ – Real Time Price. Currency in USD

37.62

-0.64 (-1.67%)

At close: Mar 27, 2026, 4:00 PM EDT

37.62

0.00 (0.00%)

After-hours: Mar 27, 2026, 7:55 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today announced that its Board of Directors has declared a quarterly cash dividend of $0.355 per share on its Class A and Class B Common Stock, payable on April 23, 2026, to shareholders of record on April 7, 2026. The quarterly dividend is equivalent to an annual dividend of $1.42 per share, an increase from.

John Wiley & Sons, Inc. (WLY) Q3 2026 Earnings Call Transcript

John Wiley & Sons, Inc. (WLY) Q3 2026 Earnings Call Transcript

John Wiley & Sons, Inc. (WLY) Q3 2026 Earnings Call Transcript

AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026

AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today reported results for the third quarter ended January 31, 2026. THIRD QUARTER SUMMARY GAAP performance vs. prior year: Revenue of $410 million up 1%; Operating Income of $63 million up 21%; and Diluted Earnings Per Share (EPS) of $0.56 compared to prior year loss of ($0.43) Adjusted Results at constant c.

Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care

Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wil.

Wiley Schedules Third Quarter 2026 Earnings Release and Conference Call

Wiley Schedules Third Quarter 2026 Earnings Release and Conference Call

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY and WLYB), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, will release its third quarter 2026 results prior to market open on Thursday March 5, 2026. The Company has scheduled a conference call beginning at 10am ET that day to discuss the results. Access webcast at Investor Relations at investors.wiley.com, or directly at http://events.q4inc.com/attendee/46.

Are You Looking for a High-Growth Dividend Stock?

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does John Wiley & Sons (WLY) have what it takes?

John Wiley & Sons: Structural Risk To Higher Education Casts A Shadow Over AI Licensing

John Wiley & Sons: Structural Risk To Higher Education Casts A Shadow Over AI Licensing

John Wiley & Sons delivers solid margin improvement and research sales growth, aided by high-margin AI licensing revenues. WLY faces structural headwinds in its learning segment due to weak white-collar job markets and potential long-term enrollment declines from LLM disruption. Despite mixed segment performance, WLY maintains strong FCF generation, robust buybacks, and a combined yield near 13% after recent price declines.

Videos

No Data

There is no data to display

Press releases

Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today announced that its Board of Directors has declared a quarterly cash dividend of $0.355 per share on its Class A and Class B Common Stock, payable on April 23, 2026, to shareholders of record on April 7, 2026. The quarterly dividend is equivalent to an annual dividend of $1.42 per share, an increase from.

AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026

AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today reported results for the third quarter ended January 31, 2026. THIRD QUARTER SUMMARY GAAP performance vs. prior year: Revenue of $410 million up 1%; Operating Income of $63 million up 21%; and Diluted Earnings Per Share (EPS) of $0.56 compared to prior year loss of ($0.43) Adjusted Results at constant c.

Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care

Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wil.

Wiley to Expand Prestigious Advanced Journals Portfolio

Wiley to Expand Prestigious Advanced Journals Portfolio

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley to significantly expand the Advanced Portfolio into life, health, and social sciences disciplines, launching eight new journals in 2026.